Introduction The company has an excellent new drug research and development team, supporting laboratories and related test equipment and equipment, which can fully ensure the development of scientific research projects. The company takes anti-tumor drugs as the main direction of new product development. It also develops drugs for the treatment of cardiovascular, cerebrovascular and digestive tract diseases, as well as independently develops high-quality compounds and intermediates. The company attaches great importance to the contact and cooperation with scientific research institutes, pays close attention to the latest achievements and scientific research directions in the international and domestic pharmaceutical industry, and is determined to forge ahead and pioneer and innovate. It has rich research and development experience in new drug research and development, forming a virtuous cycle of staged and uninterrupted research and development. To become a company with scientific research and development capabilities that closely connects research with the market and takes into account both scientific research results and economic benefits. Team The R&D management team is composed of a group of returned Ph.D.s with rich experience in foreign new drug R&D and management. Many of them have worked for famous pharmaceutical companies in the United States, and they continue to attract senior research talents at home and abroad to join. 4 people have doctorate degrees in medicine, including 2 people who have doctorate degrees from well-known foreign universities; 12 people have master's degrees, and 50 people have bachelor's degrees. The autonomy of knowledge and high degree of innovation have become a solid guarantee for providing high-quality products. At present, there are several new drug varieties in different stages of development including application for clinical approval, clinical research or application for production. The company can develop 3-4 pharmaceutical intermediates every year. As a result, nearly 30 new pharmaceutical intermediates have been developed; the ones that have obtained production approval documents from the State Food and Drug Administration include: Oxaliplatin and Oxaliplatin for Injection Disodium Clodronate and Disodium Clodronate Capsules, Clodronate Disodium Injection Setrolast and Setrolast Tablets Cisplatin Injection Dacarbazine Zoledronic Acid for Injection and Zoledronic Acid Hydrochloride Azasetron Hydrochloride and Azasetron Hydrochloride Ifosfamide for injection and ifosfamide for injection norcantharidin sodium for injection praziquantel film-coated tablets pemetrexed disodium and pemetrexed disodium for injection